Healthcare Resource Utilization And Economic Burden Of Cytokine Release Syndrome (Crs) And Neurologic Events (Ne) In Patients (Pts) With Relapsed/Refractory Multiple Myeloma (Rrmm) Receiving Idecabtagene Vicleucel (Ide-Cel, Bb2121) In Karmma.
JOURNAL OF CLINICAL ONCOLOGY（2020）
摘要
61Background: Incidence, healthcare resource utilization (HRU), and management costs associated with CRS and NE were assessed among pts in the KarMMa trial (NCT03361748) treated with ide-cel, a BCM...
更多查看译文
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要